Journal: Journal of Medical Virology

Article Title: Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review

doi: 10.1002/jmv.27697

Figure Lengend Snippet: Summary of the studies related to booster dose efficacy against Omicron variant

Article Snippet: 3. , COV‐BOOST is a multicenter, randomized, controlled phase 2 trial of third‐dose booster vaccination against COVID‐19. All the seven vaccines in the study yielded a great escalation of antibodies and cellular immune responses after ChAd/ChAd (Oxford–AstraZeneca) initial course and all, except one, after BNT/BNT (Pfizer BioNTech), with no safety concerns. , Munro et al. .

Techniques: Neutralization, Variant Assay, Activity Assay, Infection, Recombinant, Binding Assay

Journal: Vaccines

Article Title: Long-Term Antibody Response against SARS-CoV-2 in Health Care Workers: Effectiveness of Homologous and Heterologous Regimens and Their Relation to Systemic Vaccine-Associated Symptoms

doi: 10.3390/vaccines10101599

Figure Lengend Snippet: Outline of the study flow illustrating the timeline for recruiting participants according to vaccine regimens. Green: BNT/BNT, the BNT162b2 mRNA vaccine from Pfizer/BioNTech. Blue: m1273/m1273, the mRNA-1273 vaccine from Moderna. Purple: ChAd/m1273, the heterologous vaccine regimen combining ChAdOx1 vaccine from AstraZeneca with m1273 from Moderna. Early and late measurement refers to antibody level on average one and six months after completion of a vaccine regimen with a second vaccine dose, respectively.

Article Snippet: We provide evidence that both the effectiveness and durability of the humoral immune responses induced by the heterologous off-label AstraZeneca/Moderna (ChAd/m1273) vaccine regimen is at least equivalent to the homologous standard vaccine regimens with either Pfizer (BNT/BNT) or Moderna (m1273/m1273) used in Denmark.

Techniques:

Journal: Vaccines

Article Title: Long-Term Antibody Response against SARS-CoV-2 in Health Care Workers: Effectiveness of Homologous and Heterologous Regimens and Their Relation to Systemic Vaccine-Associated Symptoms

doi: 10.3390/vaccines10101599

Figure Lengend Snippet: Concentration of antibodies against SARS-CoV-2 spike (S) protein in plasma at late and early measurements according to vaccine regimen. Results are presented as box plots, where the ends of the boxes define the 25th and 75th percentiles and with a line at the median. Individual values for each vaccine group appear as green circles (BNT/BNT, the BNT162b2 mRNA vaccine from Pfizer/BioNTech), blue squares (m1273/m1273, the mRNA-1273 vaccine from Moderna), and purple diamonds (ChAd/m1273, the heterologous vaccine regimen combining ChAdOx1 vaccine from AstraZeneca with m1273 from Moderna). Individuals with paired measurements (both early and late antibody measurements in the same person) are marked with a line combining the two measurements. N is the number of individuals in each vaccine group and N-paired is the number of individuals with paired measurements. The red circle indicates one participant with a PCR-confirmed infection with SARS-CoV-2 between early and late tests. Interquartile range (IQR) indicates the difference between the 75th and 25th percentile.

Article Snippet: We provide evidence that both the effectiveness and durability of the humoral immune responses induced by the heterologous off-label AstraZeneca/Moderna (ChAd/m1273) vaccine regimen is at least equivalent to the homologous standard vaccine regimens with either Pfizer (BNT/BNT) or Moderna (m1273/m1273) used in Denmark.

Techniques: Concentration Assay, Infection

Journal: Vaccines

Article Title: Long-Term Antibody Response against SARS-CoV-2 in Health Care Workers: Effectiveness of Homologous and Heterologous Regimens and Their Relation to Systemic Vaccine-Associated Symptoms

doi: 10.3390/vaccines10101599

Figure Lengend Snippet: Concentration of antibodies against SARS-CoV-2 spike (S) protein in plasma after completion of the vaccine regimen with the second dose of vaccine. Green circles: BNT/BNT, two doses BNT162b2 mRNA vaccine from Pfizer/BioNTech). Blue squares: m1273/m1273, two doses mRNA-1273 vaccine from Moderna. Purple diamonds: ChAd/m1273, the heterologous vaccine regimen combining ChAdOx1 vaccine from AstraZeneca with m1273 from Moderna. Paired measurements are marked with lines. The individual marked with red had a PCR-confirmed infection with SARS-CoV-2 between the early and late antibody measurements.

Article Snippet: We provide evidence that both the effectiveness and durability of the humoral immune responses induced by the heterologous off-label AstraZeneca/Moderna (ChAd/m1273) vaccine regimen is at least equivalent to the homologous standard vaccine regimens with either Pfizer (BNT/BNT) or Moderna (m1273/m1273) used in Denmark.

Techniques: Concentration Assay, Infection

Journal: Vaccines

Article Title: Long-Term Antibody Response against SARS-CoV-2 in Health Care Workers: Effectiveness of Homologous and Heterologous Regimens and Their Relation to Systemic Vaccine-Associated Symptoms

doi: 10.3390/vaccines10101599

Figure Lengend Snippet: Concentration of antibodies against SARS-CoV-2 spike (S) protein in plasma 5 to 7 months after completion of vaccine regimen with the second dose of vaccine according to vaccine regimen and vaccine-associated symptoms (VAS). Results are presented as both individual values and as box plots, where the ends of the boxes define the 25th and 75th percentiles, and with a line at the median. Green circles: BNT/BNT, the BNT162b2 mRNA vaccine from Pfizer/BioNTech. Blue squares: m1273/m1273, the mRNA-1273 vaccine from Moderna. Purple diamonds: ChAd/m1273, the heterologous vaccine regimen combining ChAdOx1 vaccine from AstraZeneca with m1273 from Moderna. None refers to no VAS; Local refers to local VAS, and Systemic to systemic VAS. Interquartile range (IQR) indicates the difference between the 75th and 25th percentile.

Article Snippet: We provide evidence that both the effectiveness and durability of the humoral immune responses induced by the heterologous off-label AstraZeneca/Moderna (ChAd/m1273) vaccine regimen is at least equivalent to the homologous standard vaccine regimens with either Pfizer (BNT/BNT) or Moderna (m1273/m1273) used in Denmark.

Techniques: Concentration Assay